Literature DB >> 9420238

Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.

A Trkola1, W A Paxton, S P Monard, J A Hoxie, M A Siani, D A Thompson, L Wu, C R Mackay, R Horuk, J P Moore.   

Abstract

We have studied the breadth and potency of the inhibitory actions of the CC chemokines macrophage inhibitory protein 1alpha (MIP-1alpha), MIP-1beta, and RANTES against macrophage-tropic (M-tropic) primary isolates of human immunodeficiency virus type 1 (HIV-1) and of the CXC chemokine stromal cell-derived factor 1alpha against T-cell-tropic (T-tropic) isolates, using mitogen-stimulated primary CD4+ T cells as targets. There was considerable interisolate variation in the sensitivity of HIV-1 to chemokine inhibition, which was especially pronounced for the CC chemokines and M-tropic strains. However, this variation was not obviously dependent on the genetic subtype (A through F) of the virus isolates. Peripheral blood mononuclear cell donor-dependent variation in chemokine inhibition potency was also observed. Among the CC chemokines, the rank order for potency (from most to least potent) was RANTES, MIP-1beta, MIP-1alpha. Some M-tropic isolates, unexpectedly, were much more sensitive to RANTES than to MIP-1beta, whereas other isolates showed sensitivities comparable to those of these two chemokines. Down-regulation of the CCR5 and CXCR4 receptors occurred in cells treated with the cognate chemokines and probably contributes to anti-HIV-1 activity. Thus, for CCR5, the rank order for down-regulation was also RANTES, MIP-1beta, MIP-1alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420238      PMCID: PMC109387     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.

Authors:  Z Lu; J F Berson; Y Chen; J D Turner; T Zhang; M Sharron; M H Jenks; Z Wang; J Kim; J Rucker; J A Hoxie; S C Peiper; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

2.  Expression cloning of new receptors used by simian and human immunodeficiency viruses.

Authors:  H K Deng; D Unutmaz; V N KewalRamani; D R Littman
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

3.  CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages.

Authors:  H Moriuchi; M Moriuchi; C Combadiere; P M Murphy; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor.

Authors:  P D Bieniasz; R A Fridell; I Aramori; S S Ferguson; M G Caron; B R Cullen
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

5.  Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication: beta-chemokine-dependent and -independent effects.

Authors:  A Rubbert; D Weissman; C Combadiere; K A Pettrone; J A Daucher; P M Murphy; A S Fauci
Journal:  AIDS Res Hum Retroviruses       Date:  1997-01-01       Impact factor: 2.205

6.  CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.

Authors:  J He; Y Chen; M Farzan; H Choe; A Ohagen; S Gartner; J Busciglio; X Yang; W Hofmann; W Newman; C R Mackay; J Sodroski; D Gabuzda
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

7.  Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection.

Authors:  M Farzan; H Choe; K Martin; L Marcon; W Hofmann; G Karlsson; Y Sun; P Barrett; N Marchand; N Sullivan; N Gerard; C Gerard; J Sodroski
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

8.  CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

Authors:  M J Endres; P R Clapham; M Marsh; M Ahuja; J D Turner; A McKnight; J F Thomas; B Stoebenau-Haggarty; S Choe; P J Vance; T N Wells; C A Power; S S Sutterwala; R W Doms; N R Landau; J A Hoxie
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

9.  STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.

Authors:  F Liao; G Alkhatib; K W Peden; G Sharma; E A Berger; J M Farber
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

10.  HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.

Authors:  A Amara; S L Gall; O Schwartz; J Salamero; M Montes; P Loetscher; M Baggiolini; J L Virelizier; F Arenzana-Seisdedos
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

View more
  60 in total

1.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Authors:  Thomas J Ketas; Ines Frank; Per Johan Klasse; Brian M Sullivan; Jason P Gardner; Catherine Spenlehauer; Mirjana Nesin; William C Olson; John P Moore; Melissa Pope
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

6.  Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Authors:  Hubert Gaertner; Fabrice Cerini; Jean-Michel Escola; Gabriel Kuenzi; Astrid Melotti; Robin Offord; Irène Rossitto-Borlat; Rebecca Nedellec; Janelle Salkowitz; Guy Gorochov; Donald Mosier; Oliver Hartley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

7.  CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.

Authors:  Jean-Michel Escola; Gabriel Kuenzi; Hubert Gaertner; Michelangelo Foti; Oliver Hartley
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

8.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

9.  Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells.

Authors:  S M Owen; S Masciotra; F Novembre; J Yee; W M Switzer; M Ostyula; R B Lal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

10.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.